ESP-4222

Published

2025-12-31

Issue

Vol. 10 No. 12 (2025): Publishing

Section

Research Articles

License

Copyright (c) 2025 Noor Zuhair Bakheet NZ*, Al-Qayim MAJ

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The journal adopts the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which means that anyone can reuse and redistribute the materials for non-commercial purposes as long as you follow the license terms and the original source is properly cited.

Author(s) shall retain the copyright of their work and grant the Journal/Publisher rights for the first publication with the work concurrently licensed since 2023 Vol.8 No.2.

Under this license, author(s) will allow third parties to download, reuse, reprint, modify, distribute and/or copy the content under the condition that the authors are given credit. No permission is required from the authors or the publisher.

This broad license intends to facilitate free access, as well as the unrestricted use of original works of all types. This ensures that the published work is freely and openly available in perpetuity.

By providing open access, the following benefits are brought about:

  • Higher Visibility, Availability and Citations-free and unlimited accessibility of the publication over the internet without any restrictions increases citation of the article.
  • Ease of search-publications are easily searchable in search engines and indexing databases.
  • Rapid Publication – accepted papers are immediately published online.
  • Available for free download immediately after publication at https://esp.as-pub.com/index.php/ESP

 

Copyright Statement

1.The authors certify that the submitted manuscripts are original works, do not infringe the rights of others, are free from academic misconduct and confidentiality issues, and that there are no disputes over the authorship scheme of the collaborative articles. In case of infringement, academic misconduct and confidentiality issues, as well as disputes over the authorship scheme, all responsibilities will be borne by the authors.

2. The author agrees to grant the Editorial Office of Environment and Social Psychology a licence to use the reproduction right, distribution right, information network dissemination right, performance right, translation right, and compilation right of the submitted manuscript, including the work as a whole, as well as the diagrams, tables, abstracts, and any other parts that can be extracted from the work and used in accordance with the characteristics of the journal. The Editorial Board of Environment and Social Psychology has the right to use and sub-licence the above mentioned works for wide dissemination in print, electronic and online versions, and, in accordance with the characteristics of the periodical, for the period of legal protection of the property right of the copyright in the work, and for the territorial scope of the work throughout the world.

3. The authors are entitled to the copyright of their works under the relevant laws of Singapore, provided that they do not exercise their rights in a manner prejudicial to the interests of the Journal.

About Licence

Environment and Social Psychology is an open access journal and all published work is available under the Creative Commons Licence, Authors shall retain copyright of their work and grant the journal/publisher the right of first publication, and their work shall be licensed under the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).

Under this licence, the author grants permission to third parties to download, reuse, reprint, modify, distribute and/or copy the content with attribution to the author. No permission from the author or publisher is required.

This broad licence is intended to facilitate free access to and unrestricted use of original works of all kinds. This ensures that published works remain free and accessible in perpetuity. Submitted manuscripts, once accepted, are immediately available to the public and permanently accessible free of charge on the journal’s official website (https://esp.as-pub.com/index.php/ESP). Allowing users to read, download, copy, print, search for or link to the full text of the article, or use it for other legal purposes. However, the use of the work must retain the author's signature, be limited to non-commercial purposes, and not be interpretative.

Click to download <Agreement on the Licence for the Use of Copyright on Environmental and Social Psychology>.

How to Cite

Noor Zuhair Bakheet NZ, & Al-Qayim MAJ. (2025). Sex-related differences in serum Calprotectin, Acetate, and Zonulin as biomarkers for assessment of IBD. Environment and Social Psychology, 10(12), ESP-4222. https://doi.org/10.59429/esp.v10i12.4222

Sex-related differences in serum Calprotectin, Acetate, and Zonulin as biomarkers for assessment of IBD

Noor Zuhair Bakheet NZ

Department of physiology and medical physics, College of Medicine, Jabir Ibn Hayyan University for Medical & Pharmaceutical science, Kuffa, 54003, Iraq(ORCID: 0009-0003-4823-3727)

Al-Qayim MAJ

Department of physiology ,biochemistry and pharmacology, College of Veterinary Medicine, University of Baghdad, Iraq


DOI: https://doi.org/10.59429/esp.v10i12.4222


Keywords: Inflammatory Bowel Disease; Serum Calprotectin; Serum Acetate; Serum Zonulin.

Abstract

Background: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and Ulcerative colitis (UC), is a chronic inflammation of the gastrointestinal tract. Early diagnosis and effective follow-up are essential for optimal outcomes. Objectives: This study aims to determine and compare the role of serum calprotectin, acetate, and zonulin as biomarkers for the assessment of IBD. Methodology: 96 patients aged 25-55 years with IBD diagnosis were based on clinical and endoscopic features at the Gastroenterology and Hepatology Specialized Hospital, located in Najaf, Iraq. Of these, 48 were healthy people (G1; men 24 and G2; women 24) and 48 were patients diagnosed with IBD disease (G3; men 24 and G4; women 24). The blood samples were analyzed using specific ELISA kits for calprotectin, Acetate, and Zonulin levels. Results: The level of serum calprotectin was significantly higher (P<0.05) in IBD patients than in healthy controls, and between genders of IBD patients, the serum calprotectin increased in men more than in women. However, the level of serum acetate was significantly lower (P<0.05) in IBD patients than in healthy controls, and between genders of IBD patients, the serum acetate increased in men more than in women. The level of serum zonulin was significantly higher (P<0.05) in IBD patients than in healthy controls, and between genders found that serum zonulin in women was higher than in men. Conclusion: We demonstrated that serum calprotectin has a significant increase in active disease and may be used as a biomarker for diagnosing and monitoring IBD patients in routine practice. A significant increase of serum zonulin, which is a biomarker of intestinal epithelial barrier dysfunction associated with decreased serum acetate, referred to as dysbiosis. Each parameter is associated with variables not related to the baseline disease, such as sex.  

References

[1]. 1.Ma J, Piao X, Mahfuz S, Long S, Wang J. The interaction among gut microbes, the intestinal barrier and short chain fatty acids. Anim. Nutr. 2022; 9: 159–174.

[2]. 2.Mori A, Mitsuyama K, Sakemi R, Yoshioka S, Fukunaga S et al. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease. Kurume Med. J. 2021; 66: 209–215.

[3]. 3.Gohil K, Carramusa B. Ulcerative colitis and Crohn’s disease. Pharmacol Ther. 2014;39:576–7.

[4]. 4.Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349–55.

[5]. 5.Kopi TA, Shabnam S, Shahrokh M, Hamid AA, Azade AK. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: A review study. Gastroenterol. Hepatol. Bed Bench 2019; 12: 183–189.

[6]. 6.Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, et al. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Inter J Molecul Med. 2018;41:107–18.

[7]. 7.Carnazzo V, Redi S, Basile V, Natali P, Gulli F et al. Calprotectin: Two sides of the same coin. Rheumatology 2024; 63: 26–33.

[8]. 8.Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: From biomarker to biological function. Gut 2021; 70: 1978–1988.

[9]. 9.GarciaV, Perera YR, Chazin WJ. A Structural Perspective on Calprotectin as a Ligand of Receptors Mediating Inflammation and Potential Drug Target. Biomolecules 2022; 12: 519.

[10]. 10.Sprenkeler EGG, Zandstra J, Van Kleef ND, Goetschalckx I, Verstegen B et al. S100A8/A9 Is a Marker for the Release of Neutrophil Extracellular Traps and Induces Neutrophil Activation. Cells. 2022;11:236.

[11]. 11.Cronin P, Joyce SA, O’Toole PW, O’Connor EM. Dietary Fiber Modulates the Gut Microbiota. Nutrients 2021; 13: 1655.

[12]. 12.Markowiak-Kopeć P, Śliżewska K. The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. Nutrients 2020; 12: 1107.

[13]. 13.Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front. Immunol. 2019; 10: 277.

[14]. 14.Akhtar M, Chen Y, Ma Z, Zhang X, Shi D et al. Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation. Anim. Nutr. 2022; 8: 350–360.

[15]. 15.Li H, Fan L, Yang S, Tan P, Lei W et al. Lactobacillus acidophilus 6074 Fermented Jujube Juice Ameliorated DSS-induced Colitis via Repairing Intestinal Barrier, Modulating Inflammatory Factors, and Gut Microbiota. Mol. Nutr. Food Res. 2025; 69: e202400568.

[16]. 16.Khusainova G, Genkel V, Kuznetsova A, Nikushkina K, Saenko A et al. The Relationship between Serum Zonulin and Innate Immunity in Patients with Inflammatory Bowel Disease. Gastroenterology Insights. 2024; 15(1):179-190.

[17]. 17.Mickiewicz-Góra D, Sznurkowska K, Skonieczna-Żydecka K, Drozd A, Borkowska A et al. Markers of Intestinal Permeability and Inflammation in Enterally Fed Children with Cerebral Palsy. Nutrients. 2024 Jul 27;16(15):2447.

[18]. 18.Zybina NN, Nikonov EL, Gershtein ES, Memdli ZZ, Stilidi IS et al. Zonulin is a marker of epithelial and endothelial barrier functions in non-communicable diseases (narrative review). Russ. J. Evid.-Based Gastroenterol. 2022; 11: 28–44.

[19]. 19.Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:F1000 Faculty Rev-69.

[20]. 20.Szymanska E, Wierzbicka A, Dadalski M, Kierkus J. Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal Calprotectin. Journal of Clinical Medicine. 2021; 10(17):3905.

[21]. 21.Zhang Y, Si X, Yang L, Wang H, Sun Y et al. Association between intestinal microbiota and inflammatory bowel disease. Anim. Model. Exp. Med. 2022; 5: 311–322.

[22]. 22.Hodgkinson K, El Abbar F, Dobranowski P, Manoogian J, Butcher J et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin. Nutr. 2023; 42: 61–75.

[23]. 23.Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine 2021; 66: 103293.

[24]. 24.Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F et al. Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: A systematic review and meta-analysis. Inflammatory Intestinal Diseases.(2021); 6(3): 123-131.

[25]. 25.Abbas AF, Khezri S, Khalaf IA, Al-Asadi AA, Abdulrazzaq SA. Study of the Association of Vitamin D Receptor (VDR) Gene Polymorphism in Iraqi Patients with Inflammatory Bowel Disease. Iraqi Journal of Industrial Research. (2023); 10(1): 78-87.

[26]. 26.Mahmood HJ, Hashim AM, Salih AMM, Ibrahim RH, Al Mushhdany OI. Inflammatory Bowel Disease (IBD) in Mosul Hospital: A cross-Sectional Study-Analysis of Prevalence, Risk Factors, and Clinical Outcomes. Malaysian Journal of Medicine & Health Sciences. (2023); 19(5).

[27]. 27.Mohammed BI, Amin BK. Sociodemographic characteristics, smoking, and family history of patients with inflammatory bowel disease, northern part of Iraq. Medical Journal of Babylon. (2022);19(4): 615-619.

[28]. 28.SAS.2010.SAS/STAT Users Guide for Personal Computer. Release 9.13.SAS Institute, Inc., Cary, N.C., USA.

[29]. 29.Saviano A, Migneco A, Brigida M, Petruzziello C, Zanza C et al. Serum Calprotectin in the Evaluation of Gastrointestinal Diseases: An Ace up Your Sleeve? Medicina (Kaunas). 2024;60(5):762.

[30]. 30.Suárez-Ferrer C, Abadía BM, García RL, Poza CJ, Jaquotot HM et al. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease. Rev. Esp. Enferm. Dig. 2019; 111: 744–749.

[31]. 31.Okada K, Okabe M, Kimura Y, Itoh H, Ikemoto M. Serum S100A8/A9 as a Potentially Sensitive Biomarker for Inflammatory Bowel Disease. Lab. Med. 2019; 50: 370–380.

[32]. 32.Mortensen JH, Sinkeviciute D, Manon-Jensen T, Domislović V, McCall K et al. A Specific Calprotectin Neo-epitope [CPa9-HNE] in Serum from Inflammatory Bowel Disease Patients Is Associated with Neutrophil Activity and Endoscopic Severity. J. Crohns Colitis 2022; 16: 1447–1460.

[33]. 33.Wang W, Cao W, Zhang S, Chen D, Liu L. The Role of Calprotectin in the Diagnosis and Treatment of Inflammatory Bowel Disease. International Journal of Molecular Sciences. 2025; 26(5): 1996.

[34]. 34.Hovstadius H, Lundgren D, Karling P. Elevated Faecal Calprotectin in Patients with a Normal Colonoscopy: Does It Matter in Clinical Practice? A Retrospective Observational Study. Inflamm. Intest. Dis. 2021; 6: 101–108.

[35]. 35.Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT et al. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. Am. J. Gastroenterol. 2016; 111: 1796–1805.

[36]. 36.Gracie D J, Ford A C. The role of psychological stress in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology.2022. 7(8), 784-792.

[37]. 37.Bertollo, Amanda Gollo, et al. Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression. Frontiers in Neuroscience, 2025, 19: 1541075.‏

[38]. 38.Tian CM, Yang M F, Kong C, Luo D, Yue N N, Zhao H L et al. (2025). Microbiome–Gut–Brain Axis: Implications for the Links Between Inflammatory Bowel Disease and Neuropsychiatric Disorders. Journal of Inflammation Research, 18, 13183–13212.

[39]. 39.García-mateo, Sandra, et al. Healthy lifestyle is a protective factor from moderate and severe relapses and steroid use in inflammatory bowel disease: a prospective cohort study. Inflammatory Bowel Diseases, 2025, 31.1: 95-104

[40]. 40.Park SY. Age-Related Fecal Calprotectin Concentrations in Healthy Adults. Korean J Clin Lab Sci. 2020; 52:181-187

[41]. 41.Bayrakci N, Ozkan G, Kara SP, Yilmaz A, Guzel S. Serum Calprotectin Level as an Inflammatory Marker in Newly Diagnosed Hypertensive Patients. Int J Hypertens.2022: 6912502.

[42]. 42.Velasco Rodríguez-Belvís M, Viada Bris JF, Plata Fernández C, García-Salido A, Asensio Antón J et al. Normal fecal calprotectin levels in healthy children are higher than in adults and decrease with age. Paediatr Child Health. 2020 ;25(5):286-292.

[43]. 43.Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677.

[44]. 44.Singh A, Bhardwaj A, Tripathi A, Ranjan MK, Singh D, Sachdeva A et al. Burden of anxiety, depression and perceived stress in patients with inflammatory bowel disease: a cohort study from North India. Digestive Diseases and Sciences.2024. 69(3), 775-790.

[45]. 45.Iordache MM, Tocia C, Aschie M, Dumitru A, Manea M et al. Intestinal permeability and depression in patients with inflammatory bowel disease. Journal of Clinical Medicine.2022. 11(17), 5121.

[46]. 46.Taylor S E. Tend and befriend: Biobehavioral bases of affiliation under stress. Current Directions in Psychological Science.2012. 21(6), 395-399.

[47]. 47.Vanuytsel T, van Wanrooy S, Vanheel H, Vanormelingen C, Verschueren S et al. (2014). Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut, 63(8), 1293-1299.

[48]. 48.Singh A, Kaur P, Kumar M, Shafi S, Kumar P et al. The role of phytochemicals in modulating the gut microbiota: Implications for health and disease. Medicine in Microecology. 2025; 24: 100125.

[49]. 49.Ekstedt N, Jamioł-Milc D, Pieczyńska J. Importance of Gut Microbiota in Patients with Inflammatory Bowel Disease. Nutrients. 2024; 16(13):2092.

[50]. 50.Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP. Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets. Int J Mol Sci. 2022 ;23(7):3464.

[51]. 51.Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R et al. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosn J Basic Med Sci. 2021 ;21(3):270-283.

[52]. 52.Kim SK, Guevarra RB, Kim YT, Kwon J, Kim H et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J. Microbiol. Biotechnol. 2019;29:1335–1340.

[53]. 53.Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. The Lancet Gastroenterology & Hepatology.2025 ;10(6): 573–592.

[54]. 54.Zhang Y, Si X, Yang L, Wang H, Sun Y et al. Association between intestinal microbiota and inflammatory bowel disease. Anim. Model. Exp. Med. 2022;5:311–322.

[55]. 55.Kaczmarczyk O, Dąbek-Drobny A, Woźniakiewicz M, et al. Altered fecal short-chain fatty acid profile as a potential marker of disease activity in patients with ulcerative colitis and Crohn’s disease: a pilot study. Pol Arch Intern Med. 2022; 132: 16254.

[56]. 56.Bakheet NZ, Al-Qayim MAJ, Falih IB. Intestinal Anti-Inflammatory Improvement with Fenugreek Seeds as A prebiotic and Synbiotic with Lactobacillus acidophilus in Rats Experimentally Infected with Escherichia coli. The Iraqi Journal of Veterinary Medicine.2020;44(2): 1-14.

[57]. 57.Deleu S, Arnauts K, Deprez L, Machiels K, Ferrante M et al. High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis. Int J Mol Sci. 2023 ;24(1):768.

[58]. 58.Thulasinathan B, Suvilesh KN, Maram S, Grossmann E, Ghouri Y et al. The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention. Gut Microbes.2025; 17(1).

[59]. 59.Bakheet NZ, Alqayim MAJ. Improvement of intestinal functional and structural features enhanced with butyric acid produced by fenugreek synbiotic with lactobacillus acidophilus. Biochemical & Cellular Archives. 2020;20 (2).

[60]. 60.Sun QH, Liu ZJ, Zhang L, Wei H, Song LJ et al. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients. J Dig Dis. 2021;22(5):246-255.

[61]. 61.Paniagua G, Couce-Sánchez M, González-Blanco L, Sabater C, García-Fernández A et al. Comparative analysis of gut microbiome-derived short-chain fatty acids in patients with severe mental disorder: Insights from schizophrenia and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry.2025. 138, 111345.

[62]. 62.Hu S, Chen Y, Chen Y, Wang C. Depression and Anxiety Disorders in Patients With Inflammatory Bowel Disease. Front Psychiatry. 2021 Oct 8;12:714057.

[63]. 63.Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. Inflammation: Depression fans the flames and feasts on the heat. American Journal of Psychiatry.2015. 172(11), 1075-1091.

[64]. 64.Cohen, S., Kamarck, T., & Mermelstein, R. A global measure of perceived stress. Journal of Health and Social Behavior.1983. 24(4), 385-396.

[65]. 65.Zimet, G. D., Dahlem, N. W., Zimet, S. G., & Farley, G. K. The multidimensional scale of perceived social support. Journal of Personality Assessment.1988. 52(1), 30-41.

[66]. 66.Maget A, Dalkner N, Hamm C, Bengesser SA, Fellendorf FT et al. Sex differences in zonulin in affective disorders and associations with current mood symptoms. J Affect Disord. 2021;294:441-446.

[67]. 67.Büning C, Geissler N, Prager M et al. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis. 2012;18(10):1932–9.

[68]. 68.Caviglia GP, Dughera F, Ribaldone DG, et al.: Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Med. 2019;110(2):95–100.

[69]. 69.Khusainova G, Genkel V, Kuznetsova A, Nikushkina K, Saenko A et al. The Relationship between Serum Zonulin and Innate Immunity in Patients with Inflammatory Bowel Disease. Gastroenterology Insights. 2024; 15(1):179-190.

[70]. 70.Wood Heickman LK, DeBoer MD, Fasano A. Zonulin as a potential putative biomarker of risk for shared type 1 diabetes and celiac disease autoimmunity. Diabetes Metab Res Rev. 2020:e3309

[71]. 71.Schoultz I, Keita ÅV. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease—Focusing on Intestinal Barrier Function. Cells. 2019; 8(2):193

[72]. 72.Wang X, Memon AA, Palmér K, Hedelius A, Sundquist J et al. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease. BMC Gastroenterol. 2022;22(1):3.

[73]. 73.Wegh CAM, de Roos NM, Hovenier R et al. Intestinal permeability measured by urinary sucrose excretion correlates with serum zonulin and faecal calprotectin concentrations in UC patients in remission. J Nutr Metab 2019: 2472754.

[74]. 74.Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019; 56: 307-20.

[75]. 75.Lacombe LAC, Matiollo C, Rosa JSD, Felisberto M, Dalmarco EM et al. FACTORS ASSOCIATED WITH CIRCULATING ZONULIN IN INFLAMMATORY BOWEL DISEASe. Gastroenterol. 2022;59 (2).

[76]. 76.Zengil S, Laloğlu E. Evaluation of serum zonulin and occludin levels in obsessive-compulsive disorder and the effect of major depressive disorder comorbidity. Frontiers in Psychiatry.2024. 15, 1395235.

[77]. 77.García-Mateo S, Martínez-Domínguez S J, Gargallo-Puyuelo C J, Gallego B, Alfambra E et al. Healthy lifestyle is a protective factor from moderate and severe relapses and steroid use in inflammatory bowel disease: a prospective cohort study. Inflammatory Bowel Diseases.2025. 31(1), 95-104.

[78]. 78.Zhang H, Han M, He Y, Wang L, Hou W et al. Influencing factors of anxiety and depression in mixed-age patients with inflammatory bowel disease: a systematic review and meta-analysis. Psychology, Health & Medicine.2025. 1-21.



21 Woodlands Close #02-10, Primz Bizhub,Postal 737854, Singapore

Email:editorial_office@as-pub.com